Study shows proof of concept of BioIVT HEPATOPAC cultures with targeted assay to evaluate bioactivation potential and drug-induced liver injury (DILI) risk

(Rana Healthcare Solutions LLC) New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment.